JAMP ACITRETIN DIN 02565463
Health Canada record
| Active ingredient(s) | ACITRETIN 10 MG |
|---|---|
| Dosage form | Capsule |
| Route | Oral |
| Schedule | PRESCRIPTION |
| Class | Human |
| ATC | D05BB02 ACITRETIN |
| Original market date | |
| Current status date | 06-Feb-2026 |
| Source | Health Canada DPD |
Establishment licence of the holder
Jamp Pharma Corporation — licence 100590, currently licensed, last inspection rating C (2025-01-13).
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing ACITRETIN
| DIN | Product | Company | Form | Strength | Status |
|---|---|---|---|---|---|
| 02540703 | JAMP ACITRETIN | JAMP PHARMA CORPORATION | Capsule | ACITRETIN 25 MG | Approved |
| 02468859 | MINT-ACITRETIN | MINT PHARMACEUTICALS INC | Capsule | ACITRETIN 25 MG | Marketed |
| 02468840 | MINT-ACITRETIN | MINT PHARMACEUTICALS INC | Capsule | ACITRETIN 10 MG | Marketed |
| 02070863 | SORIATANE | ALLERGAN INC | Capsule | ACITRETIN 25 MG | Marketed |
| 02070847 | SORIATANE | ALLERGAN INC | Capsule | ACITRETIN 10 MG | Marketed |
| 02466082 | TARO-ACITRETIN | TARO PHARMACEUTICALS INC | Capsule | ACITRETIN 25 MG | Marketed |
| 02466074 | TARO-ACITRETIN | TARO PHARMACEUTICALS INC | Capsule | ACITRETIN 10 MG | Marketed |
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|---|---|---|
| 36844 | 2026-02-06 | Supplement to an Abbreviated New Drug Submission (SANDS) | Addition of new strength: 10 mg. Update to Product Monograph (to align with CRP approved PM). |
International API supply for ACITRETIN
2 valid EDQM Certificates of Suitability from 2 holders. 9 active FDA Drug Master Files.
Request a quote for JAMP ACITRETIN